# V3.16.1 fresh Architecture runtime-resume evidence

Date: 2026-08-15
Review authority: fresh Architecture Round 50, independently reviewing the
Requirements Round 169 carrier and PostgreSQL runtime-resume repair.
Result: `PASS`
Findings: `P0=0 P1=0 P2=0`

## Immutable subject

- Protected implementation parent: `d2767236dbb3cfce5bb37a30daf8aa952697262e`
- Requirements implementation commit: `f67f2af77b42ee4b2c0386a4c542ecb7bbce6eaf`
- Requirements evidence carrier: `2a461382f4a232d4c2cc5a1193d2eef9896e191d`
- Final repair-closure commit/tree: `2a461382f4a232d4c2cc5a1193d2eef9896e191d` / `617e218538a757b30b50903efb95e09656c9d044`
- Full reviewed implementation range: `d2767236dbb3cfce5bb37a30daf8aa952697262e..2a461382f4a232d4c2cc5a1193d2eef9896e191d`
- Active graph: `7f3a17fdd3a86fadfe583216a7f846da6e4102f9d649aeaf268c5a2d34f55cb0`

## Architecture closure

The repair preserves the single tracked producer, immutable run/job graph, lease,
idempotency and rollback boundaries. Direct PostgreSQL is used only behind the
reviewed local runtime's Keychain reference for database-heavy durable stages; the
Web consumer and external source acquisition remain unchanged. Claim and completion
carry the same authority identity across process restart, including a direct resume
at `facts_refresh`.

The 60-minute activation observation is bounded and covers only the initial reviewed
owner run. Failure still restores the prior scheduler and active runtime pointer.
There is no new public mutation surface, database role, environment secret, decision
heuristic, candidate quota or promotion path. The release remains compatible with
the existing additive schema and keeps V3, LINE, dispatch and automatic trading
disabled.

Requirements Round 169 is PASS at P0=0/P1=0/P2=0. Product correctness passes
`106/106`, and the complete authoritative workflow must rerun product/runtime,
model-runner, migration, browser, performance and structural owners against the
exact Architecture carrier before merge. Evaluation governance remains honestly
blocked for non-fabricated elapsed cohorts and is not treated as evidence of future
returns.
